Insulin combined with the DPP-4 inhibitor sitagliptin for diabetes: evaluation study
Not Applicable
- Conditions
- Type2 diabetes
Recruitment & Eligibility
- Status
- Complete: follow-up complete
- Sex
- All
- Target Recruitment
- 10000
Inclusion Criteria
Not provided
Exclusion Criteria
1 Hypersensitivity to sitagliptin 2 Patients who had severe ketosis or diabetic coma within 6 months 3 Severe infection or trauma, perioperative 4 Patients whose participation is deemed inappropriate at the discretion of the attending physician
Study & Design
- Study Type
- Observational
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method 1 Efficacy (1)HbA1c and blood glucose at 0, 3, 6 months and 1, 2 years after starting sitagliptin add-on therapy (2)Information of insulin therapy 2 Safety Hypoglycemia and other adverse events and those rates of occurrence
- Secondary Outcome Measures
Name Time Method